Clinical trials: Inflammatory Demyelinating Disease
Relapsing-remitting Multiple Sclerosis
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and…
- Trial name
- NCT00879658
- Testing
- BAF312
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Inflammatory Demyelinating Polyneuropathy
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.
- Trial name
- NCT07032662
- Testing
- Imeroprubart
- Where
- 142 sites in United States, Argentina and 28 more
- Volunteers
- 162 people
- Sponsor
- Immunovant Sciences GmbH
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with…
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases
- Trial name
- QSIT (NCT07221565)
- Testing
- Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Low-Dose Naltrexone (LDN)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Truway Health, Inc.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The purpose of the study is to assess long-term safety and tolerability of weekly doses of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- Trial name
- NCT04051944
- Testing
- Rozanolixizumab
- Where
- 14 sites in United States, Belgium and 6 more
- Volunteers
- 21 people
- Sponsor
- UCB Biopharma SRL
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.
- Trial name
- NCT05014724
- Testing
- Rozanolixizumab
- Sponsor
- UCB Biopharma SRL
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
The aim of this study is to learn more about the following treatment options in adults with CIDP: Subcutaneous self-infusion with HyQvia. Intravenous infusion with Gammagard/Kiovig.
- Trial name
- NCT02549170
- Testing
- HYQVIA, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C
- Where
- 83 sites in United States, Argentina and 20 more
- Volunteers
- 138 people
- Sponsor
- Baxalta now part of Shire
Systemic Lupus Erythematosus, Sjogren's Syndrome
Cell Surface Marker Expression in Autoimmune Diseases
This study is designed to explore the expression of cell-surface markers in the following seven disease areas: (a) systemic lupus erythematosus, (b) Sjogren's syndrome, (c) multiple sclerosis, (d) systemic sclerosis, (e) Crohn's…
- Conditions
- Systemic Lupus Erythematosus, Sjogren's Syndrome, Multiple Sclerosis, Systemic Sclerosis
- Trial name
- CASCADE (NCT03757065)
- Where
- 2 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Alpine Immune Sciences, Inc.
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP
This is a multicenter, open-label, single-dose, dose-escalation study evaluating the safety and tolerability of intravenous (IV) KINE-101 in patients with corticosteroid-refractory chronic inflammatory demyelinating…
- Trial name
- NCT07343310
- Testing
- KINE-101
- Where
- 2 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- Kine Sciences Co., Ltd.
Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
- Trial name
- CAPTIVATE (NCT06858579)
- Testing
- Claseprubart
- Where
- 201 sites in United States, Argentina and 29 more
- Volunteers
- 256 people
- Sponsor
- Dianthus Therapeutics
Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.
- Trial name
- NCT06637072
- Testing
- Efgartigimod PH20 SC
- Where
- 13 sites in United States
- Volunteers
- 23 people
- Sponsor
- argenx
Chronic Inflammatory Demyelinating Polyneuropathy
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)…
- Trial name
- NCT06752356
- Testing
- Immune globulin (human) 10% solution for intravenous administration
- Where
- 5 sites in United States
- Volunteers
- 161 people
- Sponsor
- Kedrion S.p.A.
Crohn's Disease, Prenatal Exposure
Pregnancy Exposure Registry for Tysabri®
The primary objective of the Registry was to evaluate the outcomes of pregnancy in women with Multiple Sclerosis (MS) or Crohn's Disease (CD) who were exposed to TYSABRI® at any time within 90 days prior to first day of Last…
- Conditions
- Crohn's Disease, Prenatal Exposure, Multiple Sclerosis, Pregnancy
- Trial name
- NCT00472992
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- Biogen
Chronic Inflammatory Demyelinating Polyneuropathy
Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
Patients diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy were confirmed based on the European Federation of Neurological Societies/ Peripheral. Nerve Society Guideline.
- Trial name
- NCT01824251
- Testing
- NPB-01
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Objectives: Part A: Efficacy of SAR445088 across three subpopulations of CIDP patients: standard of care (SOC)-Treated, SOC-Refractory and SOC-Naive Part B:Long-term safety and tolerability of SAR445088 in CIDP Secondary…
- Trial name
- NCT04658472
- Testing
- SAR445088 (IV), SAR445088 (SC)
- Where
- 32 sites in United States, Canada and 8 more
- Volunteers
- 98 people
- Sponsor
- Bioverativ, a Sanofi company
Multiple Sclerosis, Ulcerative Colitis
Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects
The goal of this clinical trial is to learn how Ozanimod drug can be administered to the healthy subjects via transdermal delivery system (TDS, patch) to achieve better drug absorption and delivery than via oral capsules…
- Trial name
- NCT06528665
- Testing
- ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults
- Where
- Malaysia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Corium Innovations, Inc.
Chronic Inflammatory Demyelinating Polyneuropathy
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic demyelinating polyneuropathy of autoimmune origin with a progressive or relapsing course.
- Trial name
- HELIPAD 1 (NCT03779828)
- Testing
- HOME LINK
- Where
- 10 sites in France
- Volunteers
- 11 people
- Sponsor
- CSL Behring
Primary Progressive Multiple Sclerosis, Primary Progressive MS
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
- Conditions
- Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
- Trial name
- NCT07840326
- Testing
- SUN-627
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sundance Biosciences, Inc.
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- emnergize (NCT07091630)
- Testing
- Empasiprubart IV
- Where
- 89 sites in United States, Argentina and 23 more
- Volunteers
- 160 people
- Sponsor
- argenx
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The purpose of the study is to evaluate clinical efficacy of rozanolixizumab as a treatment for subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- Trial name
- MyCIDPchoice (NCT03861481)
- Testing
- Rozanolixizumab
- Where
- 22 sites in United States, Belgium and 6 more
- Volunteers
- 34 people
- Sponsor
- UCB Biopharma S.P.R.L.
Polyneuropathy, Inflammatory Demyelinating, Chronic
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating…
- Trial name
- LTS (NCT06859099)
- Testing
- Riliprubart Prefilled Pen (PFP)
- Where
- 63 sites in United States, Argentina and 22 more
- Volunteers
- 300 people
- Sponsor
- Sanofi